Biological markers in osteoarthritis

Nature Clinical Practice Rheumatology

Volumn 3, Issue 6, 2007, Pages 346-356

  Rousseau, Jean Charles ^a   Delmas, Pierre D ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECAN; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCITONIN; CENTCHROMAN; CHONDROITIN SULFATE; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; CYCLOOXYGENASE 2 INHIBITOR; GLUCOSAMINE SULFATE; IBUPROFEN; INTERLEUKIN 1; MATRIX METALLOPROTEINASE; MILK PROTEIN; OSTEOCALCIN; PENTOSIDINE; PLACEBO; PROTEINASE; PROTEOGLYCAN; PYRIDINOLINE; RISEDRONIC ACID; ROFECOXIB; SOYBEAN PROTEIN; STROMELYSIN; TANOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

BONE DENSITY; BONE METABOLISM; BONE RADIOGRAPHY; BONE TURNOVER; CARBOXY TERMINAL SEQUENCE; CLINICAL EFFECTIVENESS; COLLAGEN SYNTHESIS; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG MECHANISM; DRUG RESPONSE; GENE IDENTIFICATION; GENE MUTATION; GENETIC MARKER; HIP OSTEOARTHRITIS; HUMAN; INTERMETHOD COMPARISON; KNEE OSTEOARTHRITIS; METABOLOMICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN URINE LEVEL; REVIEW; SIGNAL TRANSDUCTION; SYNOVIUM;

BIOLOGICAL MARKERS; BONE AND BONES; CARTILAGE; HUMANS; OSTEOARTHRITIS; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE;

EID: 34249890500     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0508     Document Type: Review

References (63)

1. Blackburn WD Jr et al. (1996) Cartilage imaging in osteoarthritis. Semin Arthritis Rheum 25: 273-281
2. Fex E et al. (1996) Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. Br J Rheumatol 35: 1106-1115
3. Garnero P et al. (2000) Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 43: 953-968
4. 2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 179: 405-412
5. Bauer DC et al. (2006) Classification of osteoarthritis biomarkers: A proposed approach. Osteoarthritis Cartilage 14 723-727
6. Stewart A et al. (1999) Bone density and bone turnover in patients with osteoarthritis and osteoporosis. J Rheumatol 126: 622-626
7. Bettica P et al. (2002) Evidence for increased bone resorption in patients with progressive knee osteoarthritis: Longitudinal results from the Chingford study. Arthritis Rheum 46: 3178-3184
8. Sowers M et al. (1999) The associations of bone mineral density and bone turnover markers with osteoarthritis of the hand and knee in pre- and perimenopausal women. Arthritis Rheum 42: 483-489
9. Hunter DJ et al. (2003) The role of bone metabolism in osteoarthritis. Curr Rheumatol Rep 5: 15-19
10. Elsaid KA and Chichester CO (2006) Review: Collagen markers in early arthritic diseases. Clin Chim Acta 365: 68-77
11. Shinmei M et al. (1993) Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarthritis Cartilage 1: 121-128
12. Nelson F et al. (1998) Evidence for altered synthesis of type II collagen in patients with osteoarthritis. J Clin Invest 102: 2115-2125
13. Rousseau JC et al. (2004) Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 12: 440-447
14. Olsen A et al. (2007) Anabolic and catabolic function of chondrocytes ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage 15: 335-342
15. 2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis. Osteoarthritis Cartilage 13: 258-265
16. Charni N et al. (2005) Urinary type II collagen helica peptide (HELIX-II) as a new biochemical marker of cartilage degradation in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 52: 1081-1090
17. Christgau S et al. (2001) Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone 29: 209-215
18. Rizkalla G et al. (1992) Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. J Clin Invest 90: 2268-2277
19. Vilim V et al. (2001) Serum cartilage oligomeric matrix protein reflects the presence of clinically diagnosed synovitis in patients with knee osteoarthritis. Osteoarthritis Cartilage 9: 612-618
20. Verzijl N et al. (2003) AGEing and osteoarthritis: A different perspective. Curr Opin Rheumatol 15: 616-622
21. Lohmander LS et al. (2005) Use of the plasma stromelysin (matrix metalloproteinase 3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum 52: 3160-3167
22. Dean DD et al. (1989) Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J Clin Invest 84: 678-685
23. Garnero P et al. (2001) Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: Relations with disease activity and joint damage. Ann Rheum Dis 60: 619-626
24. Elliott AL et al. (2005) Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis Rheum 52: 105-111
25. Johansen JS et al. (1996) Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 35: 553-559
26. Dragomir AD et al. (2002) Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage 10: 687-691
27. Bleasel JF et al. (1999) Changes in serum cartilage marker levels indicate altered cartilage metabolism in families with the osteoarthritis-related type II collagen gene COL2A1 mutation. Arthritis Rheum 42: 39-45
28. Kelman A et al. (2006) Association of higher levels of serum cartilage oligomeric matrix protein and N-telopeptide crosslinks with the development of radiographic hip osteoarthritis in elderly women. Arthritis Rheum 54: 236-243
29. Sowers M et al. (2002) C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 10: 595-601
30. Lohmander LS et al. (1996) Procollagen II C-propeptide in joint fluid: Changes in concentration with age, time after knee injury, and osteoarthritis. J Rheumatol 23: 1765-1769
31. Chevalier X et al. (2005) Biological markers for osteoarthritis: an update. Joint Bone Spine 72: 106-109
32. Takahashi M et al. (2004) Relationship between radiographic grading of osteoarthritis and the biochemical markers for arthritis in knee osteoarthritis. Arthritis Res Ther 6: R208-R212
33. Clark AG et al. (1999) Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: The Johnston County Osteoarthritis Project. Arthritis Rheum 42: 2356-2364
34. Garnero P et al. (2004) Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis Rheum 50: 3137-3144
35. Bruyere O et al. (2003) Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol 30: 1043-1050
36. Sugiyama S et al. (2003) Procollagen II C propeptide level in the synovial fluid as a predictor of radiographic progression in eady knee osteoarthritis. Ann Rheum Dis 62: 27-32
37. Reijman M et al. (2004) A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum 50 2471-2478
38. Mazieres B et al. (2006) Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. The ECHODIAH Cohort. Ann Rheum Dis 65: 354-359
39. Bruyere O et al. (2006) Osteoarthritis, magnetic resonance imaging and biochemical markers: A one year prospective study. Ann Rheum Dis 65: 1050-1054
40. Mazzuca SA et al. (2006) Associations between joint space narrowing and molecular markers of collagen and proteoglycan turnover in patients with knee osteoarthritis. J Rheumatol 33: 1147-1151
41. Deberg MA et al. (2005) One-year increase of Coll 2-1, a new marker of type II collagen degradation, in urine is highly predictive of radiological OA progression. Osteoarthritis Cartilage 13: 1059-1065
42. Chevalier X et al. (2001) Tissue inhibitor of metalloprotease-1 (TIMP-1) serum level may predict progression of hip osteoarthritis. Osteoarthritis Cartilage 9: 300-307
43. Pavelka K et al. (2004) Hyaluronic acid levels may have predictive value for the progression of knee osteoarthritis. Osteoarthritis Cartilage 12: 277-283
44. Sharif M et al. (2004) Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 50: 2479-2488
45. Garnero P et al. (2002) Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46: 2613-2624
46. Sharif M et al. (2007) A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis - association with disease progression. Rheumatology (Oxf) [doi 10.1093/rheumatology/kel409]
47. Garnero P et al. (2006) Increased urinary type II collagen helical and C-telopeptide levels are independently associated with a rapidly destructive hip osteoarthritis. Ann Rheum Dis 65: 1639-1644
48. Sharma L et al. (2004) The ratio of collagen breakdown to collagen synthesis and its relationship with the progression of knee osteoarthritis. Presented at the 68th Annual Scientific Meeting of the American College of Rheumatology: 2004 October 17-21 San Antonio, TX, USA: S642
49. Lehmann HJ et al. (2002) Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. Ann Rheum Dis 61: 530-533
50. Spector TD et al. (2005) Effect of risedronate on joint structure and symptoms of knee osteoarthritis: Results of the BRISK randomized; controlled trial [ISRCTN01928173]. Arthritis Res Ther 7: R625-R633
51. Gineyts E et al. (2004) Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Ann Rheum Dis 63: 857-861
52. Gineyts E et al. (2004) Effects of rofecoxib on urinary excretion of type II collagen C-telopeptide (CTX II) and glucosyl-galactosyl-pyridinoline (GLC GAL PYD) levels, markers of cartilage and synovium degradation respectively in patients with osteoarthritis (OA) of the knee. Presented at the 68th Annual Scientific Meeting of the American College of Rheumatology: 2004 October 17-21 San Antonio, TX, USA: S344
53. Bruyere O et al. (2004) Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: Evidence from two 3-year studies. Menopause 11: 138-143
54. Christgau S et al. (2004) Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 22: 36-42
55. Cibere J et al. (2005) Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: Randomized discontinuation trial results employing biomarkers. J Rheumatol 32: 896-902
56. Leff RL et al. (2003) Molecular changes in human osteoarthritic cartilage after 3 weeks of oral administration of BAY 12-9566, a matrix metalloproteinase inhibitor. J Rheumatol 30: 544-549
57. Christgau S et al. (2004) Suppression of elevated cartilage turnover in postmenopausal women and in ovarlectornized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 11: 508-518
58. Arjmandi BH et al. (2003) Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J Clin Endocrinol Metab 88: 1048-1054
59. Manicourt DH et al. (2006) Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum 54: 3205-3211
60. Lamers RJ et al. (2005) Identification of an urinary metabolite profile associated with osteoarthritis. Osteoarthritis Cartilage 13: 762-768
61. Peach CA et al. (2005) Recent advances in the genetic investigation of osteoarthritis. Trends Mol Med 11: 186-191
62. Kamarainen OP et al. (2006) Aggrecan core protein of a certain length is protective against hand osteoarthritis. Osteoarthritis Cartilage 14: 1075-1080
63. Pratta MA et al. (2006) Development and characterization of a highly specific and sensitive sandwich ELISA for detection of aggrecanase-generated aggrecan fragments. Osteoarthritis Cartilage 14: 702-713